Clinical Trial

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

Study acronym: MRD-DUCHESS
Recruiting
View on ClinicalTrials.gov →
Summary
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-19; most recent amendment 2025-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-02-07
Trial Details
NCT Number NCT06744296
Lead Sponsor Massachusetts Eye and Ear Infirmary
Collaborators: Haystack Oncology, Inc.
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 75 participants
Start Date 2025-02-03
Primary Completion 2027-01-06 (estimated)
Study Completion 2029-01-06 (estimated)
Updated on ClinicalTrials.gov 2025-05-18